The Oncology Institute, Inc.
TOI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $393 | $324 | $252 | $203 |
| % Growth | 21.3% | 28.4% | 24.4% | – |
| Cost of Goods Sold | $339 | $265 | $200 | $162 |
| Gross Profit | $54 | $60 | $52 | $41 |
| % Margin | 13.7% | 18.4% | 20.6% | 20.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $114 | $137 | $134 | $87 |
| Operating Expenses | $114 | $137 | $134 | $87 |
| Operating Income | -$60 | -$77 | -$82 | -$46 |
| % Margin | -15.3% | -23.8% | -32.5% | -22.6% |
| Other Income/Exp. Net | -$5 | -$6 | $82 | $34 |
| Pre-Tax Income | -$65 | -$83 | -$0 | -$12 |
| Tax Expense | $0 | -$0 | -$0 | -$1 |
| Net Income | -$65 | -$83 | $0 | -$11 |
| % Margin | -16.4% | -25.6% | 0.1% | -5.4% |
| EPS | -0.71 | -0.92 | 0.001 | -0.16 |
| % Growth | 22.8% | -102,322.2% | 100.6% | – |
| EPS Diluted | -0.71 | -0.92 | -0.21 | -0.16 |
| Weighted Avg Shares Out | 75 | 74 | 73 | 66 |
| Weighted Avg Shares Out Dil | 75 | 74 | 81 | 66 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $7 | $7 | $4 | $0 |
| Depreciation & Amortization | $6 | $6 | $4 | $3 |
| EBITDA | -$54 | -$54 | -$68 | -$42 |
| % Margin | -13.7% | -16.7% | -26.8% | -20.7% |